Sugi Predict

Sugi Predict / Compounds / SCHEMBL10173266

SCHEMBL10173266

SCHEMBL10173266

Nc1ccc(-c2cn3cc(N)cnc3n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 10/20 0.62
▸ KMT2A Q03164 4/20 0.62
▸ KDM4E B2RXH2 8/20 0.49
▸ SMN1; SMN2 Q16637 6/20 0.49
▸ MAPT P10636 5/20 0.49
▸ APP P05067 2/20 0.49
▸ ALDH1A1 P00352 8/20 0.43
▸ POLB P06746 2/20 0.43
▸ GFER P55789 1/20 0.43
▸ NPC1 O15118 7/20 0.43
▸ GAA P10253 5/20 0.43
▸ HPGD P15428 4/20 0.43
▸ GLA P06280 3/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ TP53 P04637 2/20 0.43
▸ CDC7 O00311 1/20 0.39
▸ DAPK3 O43293 1/20 0.39
▸ DYRK3 O43781 1/20 0.39
▸ ROCK2 O75116 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2542616 0.89 RAB9A (0.50) RAB9AKMT2AKDM4ESMN1; SMN2MAPT
SCHEMBL31154242 0.88 ALDH1A1 (0.57) RAB9AKMT2AKDM4ESMN1; SMN2MAPT
SCHEMBL5776840 0.85 RAB9A (0.57) RAB9AKMT2AKDM4ESMN1; SMN2MAPT
SCHEMBL1494735 0.77 RAB9A (1.00) RAB9AKMT2AKDM4ESMN1; SMN2MAPT
SCHEMBL16132084 0.75 ALDH1A1 (0.38) RAB9AKMT2AAPPALDH1A1POLB
SCHEMBL2127350 0.73 APP (0.69) RAB9AKMT2AKDM4ESMN1; SMN2APP
SCHEMBL7508553 0.72 RAB9A (0.62) RAB9AKMT2AKDM4ESMN1; SMN2MAPT
SCHEMBL13391908 0.71 GRM5 (0.33) RAB9AKMT2AKDM4ESMN1; SMN2MAPT
SCHEMBL15101433 0.70 RAB9A (0.59) RAB9AKMT2AKDM4ESMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL31600802 0.69 GRM5 (0.33) ALDH1A1HPGDHSD17B10ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356182-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2022-11-10 — — US disclosed
US-11053243-B2 Inhibitors of hepatitis C virus replication MERCK SHARP & DOHME CORP. (US) 2021-07-06 — — US disclosed
US-20200262836-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2020-08-20 — — US disclosed
US-20190127365-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2019-05-02 — — US disclosed
US-20170008906-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2017-01-12 — — US disclosed
US-20170008906-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2017-01-12 — — US disclosed
US-20150246917-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2015-09-03 — — US disclosed
US-20150246917-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2015-09-03 — — US disclosed
US-9090661-B2 Inhibitors of hepatitis C virus replication MERCK SHARP & DOHME CORP. (US) 2015-07-28 — — US disclosed
US-9090661-B2 Inhibitors of hepatitis C virus replication MERCK SHARP & DOHME CORP. (US) 2015-07-28 — — US disclosed
US-20140371138-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2014-12-18 — — US disclosed
US-20140371138-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2014-12-18 — — US disclosed
US-8871759-B2 Inhibitors of hepatitis C virus replication MERCK SHARP & DOHME CORP. (US) 2014-10-28 — — US disclosed
US-8871759-B2 Inhibitors of hepatitis C virus replication MERCK SHARP & DOHME CORP. (US) 2014-10-28 — — US disclosed
US-20120083483-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP (NJ) 2012-04-05 — — US disclosed
US-20120083483-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP (NJ) 2012-04-05 — — US disclosed
WO-2010111483-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2010-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200262836-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 RAB9A 1863/4885KMT2A 4309/4885KDM4E 3780/4885
US-20120083483-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 RAB9A 1863/4885KMT2A 4309/4885KDM4E 3780/4885
US-20140371138-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 RAB9A 1863/4885KMT2A 4309/4885KDM4E 3780/4885
US-20170008906-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 RAB9A 1863/4885KMT2A 4309/4885KDM4E 3780/4885
US-20150246917-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 RAB9A 1863/4885KMT2A 4309/4885KDM4E 3780/4885
US-11053243-B2 Inhibitors of hepatitis C virus replication HAVCR2, HCCS, EIF2AK2 RAB9A 1863/4885KMT2A 4309/4885KDM4E 3780/4885
US-20190127365-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 RAB9A 1863/4885KMT2A 4309/4885KDM4E 3780/4885
US-20220356182-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 RAB9A 1863/4885KMT2A 4309/4885KDM4E 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.